Hospital floor, person with mask and protection suit, walking, unfixing the mask, two more people in the back, 06/2015, (General, Photography, Doctor/Physician, Hospital)
icon-infectious-disease-testing
COVID-19

Diagnostic testing

QIAstat-Dx, QIAstat-Dx analyzer, syndromic testing, instrument, cartridge QIAstat-Dx, QIAstat-Dx analyzer, syndromic testing, instrument, cartridge, technician, woman, lab tech, lab, laboratory
*The number of targets/pathogens detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panels is different in different countries.
Syndromic testing with QIAstat-Dx

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN has developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge enables detection of the SARS-CoV-2 virus that causes COVID-19 in addition to 20+ other respiratory pathogens.*

Rapid, high-throughput targeted testing with NeuMoDx

The NeuMoDx 96 and NeuMoDx 288 systems offer a rapid and fully automated PCR test for the detection of SARS-CoV-2, under FDA Emergency Use Authorization, that can deliver a result within an hour. A new multiplex test for influenzas A/B, respiratory syncytial virus (RSV) and the SARS-CoV-2 virus is in development. NeuMoDx systems provide an ideal solution for hospitals or central testing labs, delivering the speed and flexibility to support the large numbers of patient samples they receive.

NeuMoDx, NMDx, N96, N288, NeuMoDx 96, NeuMoDx 288, automation, infectious disease, IDx, molecular diagnostics, MDx, instrument
mo-screen corona antigen test, mo-screen, coronavirus, antigen test
Now available: Reliable antigen results in 15 minutes

Now available as part of the complete QIAGEN portfolio of COVID-19 solutions is the mö-screen Corona Antigen Test. This rapid antigen test provides results in 15 minutes from using either nasal ornasopharyngeal swab specimens

Coming soon: Scalable, digital SARS-CoV-2 infection testing

QIAGEN is developing the QIAreach SARS-CoV-2 Antigen Test, a scalable, digital assay for the in vitro detection of the SARS-CoV-2 nucleocapsid protein antigen.

The QIAreach SARS-CoV-2 Antigen Test will let you test up to eight patients at once for SARS-CoV-2 infection – with first positive results in just two minutes.

coronavirus
The QIAreach SARS-CoV-2 Antigen Test is currently under development and is coming soon.
Access eHub Tests, instrument, Anti-CoV2, eSticks, Processing tubes, sample, Immune Response, Access Anti-SARS-CoV-2 Total, rapid, qualitative detection of total antibodies to SARS-CoV-2, digital lateral flow serological test, nanoparticle fluorescence, qualitative detection of total antibodies to SARS-CoV-2 in human serum and plasma (heparin, EDTA)
The QIAreach Anti-SARS-CoV-2 Total Test is currently under development and is coming soon.
Detect SARS-CoV-2 antibodies in just three minutes

To enable accessible and accurate SARS-CoV-2 antibody testing, QIAGEN is developing the QIAreach Anti-SARS-CoV-2 Total Test (Anti-CoV2). The Anti-CoV2 test will enable rapid, qualitative detection of total antibodies to SARS-CoV-2. Features include Total Ig detection (IgA, IgM, and IgG), results in approximately 10 minutes, and the ability to test up to 8 patients simultaneously on the digital QIArearch eHub. 

The complete QIAreach solution

The QIAreach eHub sets new standards in throughput and flexibility for SARS-CoV-2 testing. This digital portable device was designed for ease of use, reliability and integrated data management. Using the eStick system, it can run both the QIAreach Anti-SARS-CoV-2 Total Test and QIAreach SARS-CoV-2 Antigen Test interchangeably.

Rapid portable test
scientist, laboratory, labworker, check, reaserch, monitor, round, machine, instrument, female asian scientist in a lyb inviroment wearing a mask
QIAGEN support in testing protocols for emergency use

QIAGEN supports several testing protocols, including U.S. CDC, WHO, China CDC and Japan CDC, by providing test components, mid- to high-throughput automation solutions, and a multiplex syndromic detection solution. 

Product availability varies by country. Please contact your country representative or complete the support request form for further details. Please also review the protocols themselves for alternative solutions from other suppliers.

For QIAcube classic information please visit our resource hub.
RNA extraction solutions

Given the current public health emergency with COVID-19, QIAGEN and other companies are facing unprecedented demand for viral RNA isolation solutions. QIAGEN has developed dedicated solutions for viral RNA isolation that have been optimized for maximum sensitivity and reproducibility. 

We recognize that currently, scientists are seeking to use various QIAGEN kits, such as RNeasy, for SARS-CoV-2 RNA isolation from respiratory samples. It is critical to note that these kits have not been designed for isolating viral RNA, and performance of each kit varies. The user must consult the product-specific handbook or user manual. We strongly recommend using only dedicated RNA isolation products for SARS-CoV-2, such as those listed below:

Solutions authorized for use for COVID-19 testing in some regions (please check local regulations)

group of scientist, talk, discussion, laboratory, diversity, wearing masks
For QIAcube classic information please visit our resource hub.
OEM

Tailored oligonucleotides for SARS-CoV-2 detection

In our effort to support the detection of the SARS-CoV-2 virus, OEM by QIAGEN has ramped up the production of SARS-CoV-2 specific primers and probes. We provide customized oligos defined by our customers, as well as those mentioned in protocols recommended by WHO and the CDC. To meet the high demands, we are currently prioritizing the orders of SARS-CoV-2 specific oligonucleotides. In addition, we have introduced pre-manufacturing of these oligonucleotides to enable quick supply and delivery. To order, please send your requests here.

Additional COVID-19 resources

QIAGEN solutions

icon-support
How can we support your lab?
Reach a specialist about SARS-CoV-2 resources.

The QIAreach SARS-CoV-2 Antigen Test and the QIAreach Anti-SARS-CoV-2 Total Test are currently under development and are coming soon.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN/NeuMoDx kit handbook or user operator manual. QIAGEN handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor) or www.neumodx.com/client-resources.

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm